MET and non-small cell lung carcinoma: Compensatory activation of MET/STAT3 signaling is observed following PI3K/AKT inhibition in NSCLC, and is proposed to be responsible for the reduced efficacy of PI3K/AKT inhibitors in clinical trials [267].